Commercial J&J sets the tone for Q1 earnings with strong oncology growth Pharmaceutical TechnologyOff the back of J J's positive Q1, CEO Joaquin Duato forecasts strong growth acceleration for 2026, driven partially by psoriasis med IcotydeCommercialOncologyRead full story pharminent April 15, 2026 Pharmaceutical Technology Off the back of J J’s positive Q1, CEO Joaquin Duato forecasts strong growth acceleration for 2026, driven partially by psoriasis med Icotyde CommercialOncologyRead full story Post navigation Previous: Amazon launches its AI drug discovery platformNext: Adcendo secures $75m in Series C funding for ADC development Related Stories Commercial Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1 pharminent August 5, 2026 Commercial Leqembi sales grow again after subcutaneous approvals pharminent July 29, 2026 Commercial Wegovy pill launches in UK as first daily oral GLP1 for weight management pharminent July 6, 2026
